Associated Papers
CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G et al.
Frontiers in Immunology, 2023
XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation.
Sun J et al.
Oncogenesis, 2018
Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.
Wichmann C et al.
Leukemia, 2015
KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
Chaix A et al.
Oncogene, 2014
Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.
Kazi JU et al.
Journal of Cell Science, 2014
The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J et al.
The Journal of Biological Chemistry, 2009
Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.
Masson K et al.
The Biochemical Journal, 2006
Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk.
Lennartsson J et al.
Experimental Cell Research, 2003
Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction.
Lennartsson J et al.
Oncogene, 1999
Select a paper to view details